Caseware UK (AP4) 2024.0.164 2024.0.164 2025-04-302025-04-30The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2024-05-01falseother human health activities22truetruefalse 14173564 2024-05-01 2025-04-30 14173564 2023-05-01 2024-04-30 14173564 2025-04-30 14173564 2024-04-30 14173564 c:Director1 2024-05-01 2025-04-30 14173564 d:CurrentFinancialInstruments 2025-04-30 14173564 d:CurrentFinancialInstruments 2024-04-30 14173564 d:CurrentFinancialInstruments d:WithinOneYear 2025-04-30 14173564 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 14173564 d:ShareCapital 2025-04-30 14173564 d:ShareCapital 2024-04-30 14173564 d:RetainedEarningsAccumulatedLosses 2025-04-30 14173564 d:RetainedEarningsAccumulatedLosses 2024-04-30 14173564 c:OrdinaryShareClass1 2024-05-01 2025-04-30 14173564 c:OrdinaryShareClass1 2025-04-30 14173564 c:OrdinaryShareClass1 2024-04-30 14173564 c:OrdinaryShareClass2 2024-05-01 2025-04-30 14173564 c:OrdinaryShareClass2 2025-04-30 14173564 c:OrdinaryShareClass2 2024-04-30 14173564 c:OrdinaryShareClass3 2024-05-01 2025-04-30 14173564 c:OrdinaryShareClass3 2025-04-30 14173564 c:OrdinaryShareClass3 2024-04-30 14173564 c:OrdinaryShareClass4 2024-05-01 2025-04-30 14173564 c:OrdinaryShareClass4 2025-04-30 14173564 c:OrdinaryShareClass4 2024-04-30 14173564 c:FRS102 2024-05-01 2025-04-30 14173564 c:AuditExempt-NoAccountantsReport 2024-05-01 2025-04-30 14173564 c:FullAccounts 2024-05-01 2025-04-30 14173564 c:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 14173564 2 2024-05-01 2025-04-30 14173564 e:PoundSterling 2024-05-01 2025-04-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 14173564









AMICUS CLINICAL DEVELOPMENT LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2025

 
AMICUS CLINICAL DEVELOPMENT LIMITED
REGISTERED NUMBER: 14173564

BALANCE SHEET
AS AT 30 APRIL 2025

2025
2024
Note
£
£

  

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 4 
357,612
63,806

Cash at bank and in hand
  
124,079
173,894

  
481,691
237,700

Creditors: amounts falling due within one year
 5 
(324,718)
(89,767)

NET CURRENT ASSETS
  
 
 
156,973
 
 
147,933

TOTAL ASSETS LESS CURRENT LIABILITIES
  
156,973
147,933

  

NET ASSETS
  
156,973
147,933


CAPITAL AND RESERVES
  

Called up share capital 
 6 
1,000
1,000

Profit and loss account
  
155,973
146,933

  
156,973
147,933


Page 1

 
AMICUS CLINICAL DEVELOPMENT LIMITED
REGISTERED NUMBER: 14173564
    
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



Dr G M Fox
Director

Date: 30 October 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
AMICUS CLINICAL DEVELOPMENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

1.


GENERAL INFORMATION

Amicus Clinical Development Limited is a private company limited by shares and incorporated in England and Wales. Its registered office address is 177 Huntingdon Road, Cambridge, England, CB3 0DH.

The financial statements are rounded to the nearest pound (£).

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Income and Retained Earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.3

TURNOVER

Turnover comprises income related to various services provided to pharmaceutical companies with regards to clinical trials. Income arises either at the time of services being provided or once work has been completed. 
Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Page 3

 
AMICUS CLINICAL DEVELOPMENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.4

INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

PENSIONS

DEFINED CONTRIBUTION PENSION PLAN

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.6

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.7

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 4

 
AMICUS CLINICAL DEVELOPMENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.8

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 2 (2024 - 2).

Page 5

 
AMICUS CLINICAL DEVELOPMENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

4.


DEBTORS

2025
2024
£
£


Trade debtors
353,585
63,296

Prepayments and accrued income
4,027
510

357,612
63,806



5.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025
2024
£
£

Trade creditors
39,145
22,403

Corporation tax
45,279
45,563

Other taxation and social security
41,923
19,211

Other creditors
1,288
-

Accruals and deferred income
197,083
2,590

324,718
89,767



6.


SHARE CAPITAL

2025
2024
£
£
ALLOTTED, CALLED UP AND FULLY PAID



250 (2024 - 250) Ordinary A shares of £1.00 each
250
250
250 (2024 - 250) Ordinary B shares of £1.00 each
250
250
250 (2024 - 250) Ordinary C shares of £1.00 each
250
250
250 (2024 - 250) Ordinary D shares of £1.00 each
250
250

1,000

1,000


 
Page 6